CytomX director granted 59,000 stock options

CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock.

Rhea-AI Filing Summary

CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036. All 59,000 options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continuous service as a director.

Insider Trade Summary

Grant/Award: 59,000 shares

Grant/Award 1 txn

Insider Mohindru Mani

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Key Figures

Option grant size: 59,000 options Exercise price: $2.96 per share Underlying shares: 59,000 shares +2 more

5 metrics

Option grant size 59,000 options Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of options

Underlying shares 59,000 shares Underlying Common Stock tied to options

Expiration date June 16, 2036 Option expiration

Post-grant derivative holding 59,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Annual Meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of the Issuer's stockholders financial

"the date of the 2027 Annual Meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mani Mohindru report in the CytomX (CTMX) Form 4 filing?

The filing reports a grant of 59,000 stock options to director Mani Mohindru. These options give the right to buy CytomX Common Stock at a fixed price, subject to vesting conditions and an expiration date.

What is the exercise price of the new CytomX (CTMX) stock options?

The granted options have an exercise price of $2.96 per share. This is the price at which the holder may purchase CytomX Common Stock once the options vest and before they expire, assuming all vesting conditions are satisfied.

When do Mani Mohindru’s CytomX (CTMX) options vest?

All 59,000 options vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders. Vesting requires continuous service as a director until that vesting date.

When do the CytomX (CTMX) stock options granted to Mani Mohindru expire?

The options expire on June 16, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur between vesting and this expiration, subject to applicable trading and company policies.

How many CytomX (CTMX) options does Mani Mohindru hold after this grant?

Following the reported transaction, Mani Mohindru holds 59,000 stock options directly. This filing shows only this option position, which corresponds to the newly granted award disclosed in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohindru Mani

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Mani Mohindru	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)